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Nearly one-third of the world’s population is infected with latent tuberculosis (LTBI).
Tuberculosis (TB) rates in the border states are higher than national rates in both the US
and Mexico, with the border accounting for 30% of total registered TB cases in both
countries. However, LTBI rates in the general population in Mexican border states are
unknown. In this region, LTBI is diagnosed using the tuberculin skin test (TST). New
methods of detection more specific than TST have been developed, although there is
currently no gold standard for LTBI detection. Our objective is to demonstrate utility of
the Quantiferon TB gold In-Tube (QFT-GIT) test compared with the TST to detect LTBI
among border populations. This is an observational, cross-sectional study carried out in
border areas of the states of Nuevo Leon and Tamaulipas, Mexico. Participants (n = 210)
provided a TST and blood sample for the QFT-GIT. Kappa coefficients assessed the
agreement between TST and QFT-GIT. Participant characteristics were compared using
Fisher exact tests. Thirty-eight percent of participants were diagnosed with LTBI by QFT-
GIT. The proportion of LTBI detected using QFT-GIT was almost double [38% (79/210)]
that found by TST [19% (39/210)] (P < 0.001). Concordance between TST and QFT-GIT
was low (kappa =  0.37). We recommend further studies utilizing the QFT-GIT test to
detect LTBI among border populations.
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introduction
Most US–Mexico border states have high rates of unemployment and low per capita income (1). 
In these states, overcrowding, poor nutrition, and poor access to health services are common (2). 
Additionally, the US–Mexico border states have rapidly growing populations (3). The US–Mexico 
border region, extending 37 miles north and south of the border itself, accounts for 30% of total 
registered tuberculosis (TB) cases in both the US and Mexico (2), and border states from Northern 
Mexico have the highest rates of TB in the country, with rates between 15 and 39 cases per 100,000 
inhabitants (3–6). Those border states with the highest rates, such as in Baja California, Sonora, and 
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Tamaulipas, tend to reflect migration routes from the central and 
southern Mexican states, as well as Central America, toward the 
US (7). Additionally, prolonged infectiousness, increased drug 
resistance, and poor access to health services along the border 
create barriers to stemming TB disease transmission and provid-
ing adequate treatment (8–10). The migratory process itself, 
poverty, and substandard conditions are likely to be primary fac-
tors resulting in increased risk of developing active TB (5, 6, 11).
Infection with Mycobacterium tuberculosis bacilli may result in 
latent tuberculosis infection (LTBI), a carrier state where patients 
are neither symptomatic nor contagious (12). Latent TB infection 
is thus frequently not detected or diagnosed. However, when the 
host immune system fails, infection may progress to active TB 
disease, at which point symptoms may develop and disease spread 
can occur (13, 14). The overall lifetime risk of LTBI progression to 
active TB is estimated at approximately 5–10% (13, 15), with risk 
increased by underlying immunosuppression, including human 
immunodeficiency virus (HIV), diabetes, and heavy steroid use, 
conditions frequently observed along the border (6, 16–19).
Along the Mexico-US border LTBI is diagnosed using the 
tuberculin skin test (TST), an old diagnostic tool with several 
limitations in sensitivity and specificity (20, 21). Cross-reactive 
responses due to BCG vaccination or exposure to environmental 
mycobacterium can lead to false-positive results, leading to 
unnecessary follow-up (21). Additionally, high-risk groups such 
as diabetics, HIV-coinfected, or individuals receiving steroids 
may not have a detectable TST response due to compromised 
immune systems (16–19).
In the last few years, in the absence of a gold standard test 
for LTBI, new methods of detection more sensitive and specific 
than TST have been developed. These include cell-mediated 
immunity-based interferon-gamma release assays such as the 
Quantiferon TB gold In-Tube (QFT-GIT). The QFT-GIT is based 
on interferon gamma cytokine release in response to TB-specific 
antigen stimulation of peripheral lymphocytes and has shown 
equivalent sensitivity and greater specificity than TST in detect-
ing LTBI in several populations (21–23). It is important to note, 
however, that evaluations of sensitivities provide a suboptimal 
gold standard, as they utilize clinical situations where a specific 
immune response is likely to occur, such as among patients with 
either current active TB or a history of TB disease (21, 23).
Of the studies examining the prevalence of LTBI in the Mexican 
Border side, the focus has been on high-risk populations. One 
of these was a study that took place in a migrant agricultural 
community in San Quintín, Baja California, Mexico. Among 
133 participants tested with QFT-GIT, 39.8% had a positive 
test (24). Another study in Tijuana among 1,020 injecting drug 
users reported an LTBI prevalence of 67% (25). More recently, 
a case–control study was carried out among 150 patients from 
the Mestizo population of Cuidad Juárez, Chihuahua, Mexico 
(26). Finally, our previously reported study in Nuevo Leon and 
Tamaulipas showed high LTBI prevalence (~40%) among close 
contacts to active TB cases (27).
The main objective of this work is to demonstrate utility of 
the QFT-GIT test to detect LTBI among border populations in 
Mexico. These outcomes could be used to guide test choice in the 
future as well as to inform future policy regarding LTBI.
Materials and Methods
study Design and inclusion criteria
A cross-sectional study was performed from January through 
March of 2013 among participants that live in Northern Mexico. 
Patients from border areas of Nuevo Leon and Tamaulipas were 
recruited in health clinics belonging to the Nuevo Leon and 
Tamaulipas Ministries of Health. People living in urban and rural 
border areas during the above-mentioned period were invited 
to participate. Patients with active TB disease were referred for 
follow-up but excluded from the study, although family mem-
bers of these active TB patients were invited to participate in 
the study.
Patients diagnosed with cancer, patients diagnosed with 
HIV, pregnant women, and individuals using steroids for more 
than 1 month were also excluded. Patients with an incomplete 
questionnaire or who failed to show for the TST read appoint-
ment (48–72  h following the placement) were not included in 
the data analysis. This protocol was approved by Research and 
Ethics Committees from the Ministries of Health of Tamaulipas 
and University of Monterrey (UDEM). All participants, or their 
parents in case of children, signed an informed consent.
Questionnaire
Sociodemographic and clinical data were derived through 
interviewing individuals by trained public health staff using a 
standardized survey. The survey included medical diagnosis, 
age, gender, housing conditions, crowding, comorbidities such 
as diabetes and hypertension, and behavioral risk factors such 
as smoking, excess alcoholic beverages, or drug use. Responses 
were all self-reported.
Procedures
All eligible participants (n = 210) were interviewed and then tested 
for LTBI by TST and QFT-GIT. The QFT-GIT test was performed 
by trained laboratory personnel who were blinded to the patient’s 
clinical details. Peripheral blood samples were processed 4–6 h 
after being obtained from the patient. Initially, the blood was ali-
quoted into three different tubes: the first did not contain antigens 
(control), the second tube contained TB antigens, and the third 
contained phytohemagglutinin (mitogen or positive control) 
(28). These tubes were incubated for 18–24 h at 37°C. Finally, an 
ELISA test was performed to determine interferon gamma levels 
in the plasma of each tube. The results were considered positive, 
negative, or indeterminate according to the criteria established 
in the manufacturer’s software. Once the blood was removed to 
perform the QFT-GIT test, the TST was performed using the 
Mantoux method, using 0.1 mL (2 tuberculin units) of purified 
protein derivative RT23 (Statens Serum Institute; Copenhagen, 
Denmark) in the middle of the anterior face of the forearm, and 
the outcome was evaluated 48–72  h later by experienced staff. 
To read the TST, the transverse diameter of the induration was 
measured and the data registered in millimeters. The TST reac-
tion was scored as positive if the induration diameter was >5 mm. 
Individuals were considered to have a diagnosis of LTBI if they 
were asymptomatic without clinical evidence of active TB, but 
had a positive QFT-GIT and/or TST-positive reaction.
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statistical analysis
Data were entered into Microsoft Excel 2010. Statistical calcula-
tions were made with the statistical package PASW statistics 
version 18.0. The concordance between the QFT-GIT and TST 
tests was calculated using statistical kappa (κ). Strengths of agree-
ment were considered “poor” (κ ≤ 0.20), “fair” (0.20 < κ ≤ 0.40), 
“moderate” (0.40 < κ ≤ 0.60), “good” (0.60 < κ ≤ 0.80), and “very 
good” (0.80 < κ ≤  1.00). Descriptive statistics were conducted 
to describe the sample. Participants were grouped as adult, 
elderly (60 years of age or more), or pediatric (<18 years of age). 
Differences in frequencies were evaluated by the Fisher exact test. 
Statistical significance was defined by P ≤ 0.05. Sensitivity and 
specificity could not be calculated as there is currently no gold 
standard for LTBI diagnosis.
results
Participants
In this preliminary work in the border states of Nuevo Leon and 
Tamaulipas, Mexico, we evaluated 210 participants. One hundred 
and forty-seven of the participants (70%) were in contact with 
patients with active TB under treatment. The mean age of the 
participants was 31 years, and almost all (94%) were BCG vac-
cinated. The proportion of participants with diabetes was 11.9%, 
while 10% reported suffering from hypertension (Table 1).
lTBi Diagnosis
All (210) the participants were QFT-GIT tested, with 207 (99%) 
completing the TST evaluation. The proportion of LTBI detected 
using QFT-GIT was close to double [38% (79/210)] that found 
by TST [19% (39/207)] (P <  0.001) (Table  2). The proportion 
of participants with LTBI detected by QFT-GIT among close 
contacts was 49.7% (73/147) compared to 21% by TST (31/147). 
When a positive result on either test was considered evidence 
of LTBI, 40.9% (86/210) of participants were found to have 
LTBI. Individuals not considered contacts were only positive by 
TaBle 1 | Patient characteristics (N = 210).
characteristic N %
age
Adults 125 59.5
Elderly 19 9.1
Pediatric 66 31.4
gender
Male 77 30.6
Female 133 63.4
Bcg history
Yes 198 94.3
No 12 5.7
Diabetes
Yes 25 11.9
No 185 88.1
hypertension
Yes 21 10
No 189 90
Elderly, 60 years of age or more; pediatric, <18 years of age.
QFT-GIT 9.5% of the time (6/63) (P < 0.001) and by TST 12.6% 
of the time (8/63) (P < 0.01).
No significant differences were observed across gender. The 
proportion of participants with positive TST was inversely asso-
ciated with increasing age (P =  0.05). While the proportion of 
participants testing positive by QFT-GIT was higher among the 
elderly and children (Table 2), these differences were not statisti-
cally significant. The proportion of participants with positive 
QFT-GIT was significantly higher in people with diabetes (56%) 
compared to that of non-diabetics (35%) (P = 0.03). These differ-
ences could not be detected with TST. No differences were found 
in the proportion of positive QFT-GIT and TST tests among 
participants with or without hypertension.
Test concordance
The assays had a concordance of just k = 0.37 (P < 0.01) with each 
other among contacts (Table 3), approximately the same as when 
all asymptomatic people reviewed in the study were included 
(0.39) (Table  4). When close contacts of pulmonary active TB 
cases were tested with QFT-GIT and TST, some individuals 
with positive QFT-GIT had negative TST (45/73) and some 
with negative QFT-GIT had positive TST results (3/74). In this 
scenario, only 38.3% (28/73) of individuals with LTBI detected by 
QFT-GIT had a positive TST test; however, when QFT-GIT was 
negative (71/74), 95.9% of the individuals were TST negative as 
well. If the QFT-GIT results are correct, the proportion of false-
negative TST tests was 61.6% (45/73) and false positive was 4.1% 
(3/74) (Table 3).
Discussion
This study showed a high prevalence of LTBI among border 
populations. An even higher proportion of participants were 
found to have LTBI when limited to those with close contact to 
active TB patients. Higher positivity rates were observed by the 
QFT-GIT test, with many of these individuals displaying a nega-
tive TST. Test concordance between the two tests was fairly low.
Others have also shown a prevalence of close to 40% among 
migrant residents on the US side of the border, in Baja California 
(24). Given the elevated LTBI prevalence observed, there are 
likely many individuals who have active TB who are not being 
diagnosed or treated. Particularly, troubling is the high preva-
lence of LTBI among high-risk groups for progression to active 
TB, such as close contacts and individuals with comorbidities 
such as diabetes. In Mexico, most patients are not offered testing 
or treatment for LTBI, with the exception of diabetic patients 
in close contact with active TB patients, who are currently 
offered preventive treatment regardless of their LTBI status (29). 
Moreover, Mexican-born TB patients on the US border have been 
previously reported to have greater disease severity, with more 
frequent sputum smear-positive and cavitary disease, possibly 
due to more limited access or delay in seeking care (30). Delayed 
diagnoses, combined with the lack of LTBI detection, only serve 
to continue a cycle of disease transmission within and across 
households.
Given these high prevalence rates, it is essential that screening 
and appropriate preventive therapy be provided for those at high 
TaBle 4 | concordance between TsT and QFT-giT among all 
participants.
Test QFT-giT+ QFT-giT− Total
TST+ 32 7 39
TST− 47 121 168
Total 79 128 207a
k = 0.39.
aThree TSTs were not read.
TaBle 3 | concordance between TsT and QFT-giT among contacts only.
Test QFT-giT+ QFT-giT− Total
TST+ 28 3 31
TST− 45 71 116
Total 73 74 147
k = 0.37.
TaBle 2 | comparative outcomes from QFT-giT and TsT.
Distribution of patients QFT-giT P-value TsT P-value
negative Positive negative nD Positive
n = 131 n = 79 n = 168 n = 3 n = 39
age
A 81 (64.8%) 44 (35.2%) 0.67 104 (83.2%) 3 (2.4%) 18 (14.4%) 0.05
E 11 (57.9%) 8 (42.1%) 17 (89.5%) 0 (0%) 2 (10.5%)
P 39 (59.1%) 27 (40.9%) 47 (71.2%) 0 (0%) 19 (28.8%)
gender
M 49 (63.6%) 28 (36.4%) 0.44 63 (81.8%) 0 (0%) 14 (18.2%) 0.24
F 82 (61.7%) 51 (38.3%) 105 (78.9%) 3 (2.3%) 25 (18.8%)
contact
Yes 74 (50.3%) 73 (49.7%) 0.001* 116 (78.9%) 0 (0%) 31 (21.1%) 0.01*
No 57 (90.5%) 6 (9.5%) 52 (82.5%) 3 (5.8%) 8 (12.7%)
Bcg
Yes 123 (62.1%) 75 (37.9%) 0.50 157 (79.3%) 3 (1.5%) 38 (19.2%) 0.48
No 8 (66.7%) 4 (33.3%) 11 (91.7%) 0 (0%) 1 (8.3%)
Diabetes
Yes 11 (44%) 14 (56%) 0.03* 150 (81.1%) 3 (1.7%) 32 (17.2%) 0.33
No 120 (64.9%) 65 (35.1%) 18 (72%) 0 (0%) 7 (28%)
hypertension
Yes 13 (61.9%) 8 (38.1%) 0.56 152 (80.4%) 3 (1.6%) 34 (18%) 0.60
No 118 (62.4%) 71 (37.6%) 16 (76.2%) 0 (0%) 5 (23.8%)
A, adult; E, elderly, 60 years of age or more; P, pediatric, <18 years of age; M, male; F, female; ND, not done.
*Statistically significant, P < 0.05.
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risk of progression, and perhaps more broadly for workers and 
their families. However, given the early risk of isoniazid (INH) 
toxicity, persons diagnosed with LTBI will need to be counseled 
and instructed to seek medical attention if they develop TB 
symptoms having declined INH treatment (31). Targeted test-
ing of specific populations at high risk for progression to active 
disease, such as priority groups that are medically underserved or 
immune-compromised, may be helpful in curbing the progres-
sion to active TB disease (30). However, as has been previously 
noted, how to best target populations in a systematic manner is 
still unclear (32, 33).
Quantiferon TB gold In-Tube has previously been shown to 
have higher specificity compared with the TST when compared 
to patients with a positive culture, as well as a higher predictive 
ability that a test-negative individual will not develop disease or 
that a test-positive individual will progress (22). However, in this 
study, the proportion of individuals who tested positive by QFT-
GIT was greater than those testing positive by TST, indicating 
that QFT-GIT may be more likely to correctly identify individuals 
as infected with TB compared to the TST. Given these results, 
it might be important to consider QFT-GIT among high-risk 
groups who may not have a detectable TST response, such as 
diabetics, HIV-coinfected, or individuals receiving steroids or 
immunotherapy (34). As an example, in populations (such as in 
Monterrey, Nuevo Leon, Mexico) where the incidence of TB is 
20 per 100,000 habitants, this would mean that if each patient 
had a mean of five contacts, approximately 2,000 contacts would 
be located in a given year. Given the data from our study, we 
would then expect 1,200 false-negative test results with the TST. 
In essence, this means that many individuals who actually have 
LTBI are left untreated and may subsequently progress to active 
TB disease. This is particularly true in a population with many 
comorbidities that decrease immune function (16–19).
As per the authors’ prior results from the Mexico side of the 
border, we found the TST and QFT-GIT to show a low level of 
concordance (27), although this was more often due to QFT-
GIT+/TST− combinations, rather than the converse, as had 
previously been reported (27).
Since no systematic procedures have been in place to screen 
individuals for latent TB infection, we recommend a study to 
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examine the feasibility of providing infected individuals with test-
ing, follow-up screening, and treatment services. The main objec-
tive of the proposed study would be to demonstrate the potential 
utility of the QFT-GIT test to detect LTBI as well as the feasibility 
of implementation among border populations. Since LTBI is not 
routinely diagnosed, testing on the border will potentially allow 
for diagnosis and follow-up prophylaxis. An earlier version of 
the QFT-GIT has previously been shown to be cost-effective for 
targeted screening in Mexico (35). Additionally, assessing the 
LTBI status along the border will both provide an assessment of 
whether QFT-GIT should replace the TST in routine practice and 
identify predictive risk factors for LTBI in these populations. These 
results could be of particular significance because of both the costs 
and adverse effects of LTBI treatment that might occur among 
false positives as well as the possible detection using QFT-GIT 
of immunocompromised individuals (36). We are continuing this 
work in Mexico and have begun following up on this work in the 
Yuma/San Luis region in the state of Arizona in the United States.
Limitations of our study include the cross-sectional nature of 
the results, self-selection of participants into the study, as well 
as the ability to generalize these results to other parts of the 
border – the rural farmworkers sampled are more economically 
stable and far less mobile than the migrant farmworkers observed 
in many parts of the US and may not be representative of other 
farmworker groups. Another important limitation is the lack of 
culture confirmation of TB disease in Mexico. Close contacts 
were thus selected based on both a self-report and a sputum 
smear (Ziehl–Nielsen) diagnosis among the active index case, 
which is not considered confirmatory. Nevertheless, given the 
high prevalence of LTBI among the close contacts, it is likely that 
many of the index cases were at some point infectious.
An association has previously been found between travel to 
the US and the presence of LTBI (8). Initiatives to increase TB 
awareness and testing and treatment of latent TB infection and 
disease are thus critical to TB elimination efforts along the border 
region, as populations repeatedly move and work on both sides of 
the border. Binational public health action to prevent individuals 
with LTBI from progressing to TB through proper screening and 
treatment is essential for TB control and prevention, just as has 
been advocated for active TB (20). As for active TB, we believe that 
partnerships should be facilitated between healthcare providers 
for LTBI across both sides of the US–Mexico border, considering 
the border region to be one single unit, with documentation of 
effective strategies for cross-border notification of movement and 
treatment coordination (7).
Additional next steps based on this work could include 
providing populations on the border with information around 
TB and LTBI, including training and informational materials. 
Increasing service utilization is a key challenge. Poor communi-
cation, government mistrust, and misunderstanding of the health 
system are some of the barriers to effective health service delivery. 
Explaining the flow of the clinic and health system process for 
those with TB exposure may provide a significant first step. 
Such education could be integrated with existing programs and 
community health center initiatives for individuals living on the 
border.
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